These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 18977464)
1. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Seheult RD; Ruh K; Foster GP; Anholm JD Respir Physiol Neurobiol; 2009 Feb; 165(2-3):123-30. PubMed ID: 18977464 [TBL] [Abstract][Full Text] [Related]
2. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. Fischler M; Maggiorini M; Dorschner L; Debrunner J; Bernheim A; Kiencke S; Mairbäurl H; Bloch KE; Naeije R; Brunner-La Rocca HP Am J Respir Crit Care Med; 2009 Aug; 180(4):346-52. PubMed ID: 19520908 [TBL] [Abstract][Full Text] [Related]
3. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Pham I; Wuerzner G; Richalet JP; Peyrard S; Azizi M Eur J Clin Invest; 2010 Mar; 40(3):195-202. PubMed ID: 20415698 [TBL] [Abstract][Full Text] [Related]
4. Exhaled nitric oxide and pulmonary artery pressures during graded ascent to high altitude. Donnelly J; Cowan DC; Yeoman DJ; Lucas SJ; Herbison GP; Thomas KN; Ainslie PN; Taylor DR Respir Physiol Neurobiol; 2011 Aug; 177(3):213-7. PubMed ID: 21515414 [TBL] [Abstract][Full Text] [Related]
5. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Modesti PA; Vanni S; Morabito M; Modesti A; Marchetta M; Gamberi T; Sofi F; Savia G; Mancia G; Gensini GF; Parati G Circulation; 2006 Sep; 114(13):1410-6. PubMed ID: 16982943 [TBL] [Abstract][Full Text] [Related]
6. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M; Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459 [TBL] [Abstract][Full Text] [Related]
7. Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude. Dehnert C; Grünig E; Mereles D; von Lennep N; Bärtsch P Eur Respir J; 2005 Mar; 25(3):545-51. PubMed ID: 15738301 [TBL] [Abstract][Full Text] [Related]
8. Prevention of high-altitude pulmonary edema by nifedipine. Bärtsch P; Maggiorini M; Ritter M; Noti C; Vock P; Oelz O N Engl J Med; 1991 Oct; 325(18):1284-9. PubMed ID: 1922223 [TBL] [Abstract][Full Text] [Related]
9. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. Basnyat B; Hargrove J; Holck PS; Srivastav S; Alekh K; Ghimire LV; Pandey K; Griffiths A; Shankar R; Kaul K; Paudyal A; Stasiuk D; Basnyat R; Davis C; Southard A; Robinson C; Shandley T; Johnson DW; Zafren K; Williams S; Weiss EA; Farrar JJ; Swenson ER High Alt Med Biol; 2008; 9(3):209-16. PubMed ID: 18800957 [TBL] [Abstract][Full Text] [Related]
10. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198 [TBL] [Abstract][Full Text] [Related]
12. Ischemic preconditioning improves oxygen saturation and attenuates hypoxic pulmonary vasoconstriction at high altitude. Foster GP; Giri PC; Rogers DM; Larson SR; Anholm JD High Alt Med Biol; 2014 Jun; 15(2):155-61. PubMed ID: 24949710 [TBL] [Abstract][Full Text] [Related]
13. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
14. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Hebert A; Mikkelsen UR; Thilen U; Idorn L; Jensen AS; Nagy E; Hanseus K; Sørensen KE; Søndergaard L Circulation; 2014 Dec; 130(23):2021-30. PubMed ID: 25446057 [TBL] [Abstract][Full Text] [Related]
15. Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Faoro V; Boldingh S; Moreels M; Martinez S; Lamotte M; Unger P; Brimioulle S; Huez S; Naeije R Chest; 2009 May; 135(5):1215-1222. PubMed ID: 19188550 [TBL] [Abstract][Full Text] [Related]
16. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Berger RM; Beghetti M; Galiè N; Gatzoulis MA; Granton J; Lauer A; Chiossi E; Landzberg M Int J Cardiol; 2010 Oct; 144(3):373-8. PubMed ID: 19464064 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Iversen K; Jensen AS; Jensen TV; Vejlstrup NG; Søndergaard L Eur Heart J; 2010 May; 31(9):1124-31. PubMed ID: 20202971 [TBL] [Abstract][Full Text] [Related]
18. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007 [TBL] [Abstract][Full Text] [Related]
19. Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. Faoro V; Huez S; Giltaire S; Pavelescu A; van Osta A; Moraine JJ; Guenard H; Martinot JB; Naeije R J Appl Physiol (1985); 2007 Oct; 103(4):1161-5. PubMed ID: 17615281 [TBL] [Abstract][Full Text] [Related]
20. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ; J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]